Health · Pharma & Biotech · 14 hrs ago
Takeda’s narcolepsy drug is set for Japanese insurance coverage
Takeda developed an oral drug for narcolepsy type 1, a condition that can cause severe sleepiness even when people need to stay awake.
More than 3 million people worldwide are estimated to have narcolepsy, and Japan has a high rate of the condition.
The drug, called oveporexton, is scheduled for Japanese insurance coverage on October 14.
It has also been approved in China and the United States, where launches are expected by the end of the year.
Takeda is set to launch it ahead of competing treatments being developed by other drug companies.
The company forecasts peak annual sales of $2 billion to $3 billion for the drug.
Takeda Pharmaceutical’s oral narcolepsy type 1 drug Ozeifuru is scheduled for Japanese insurance coverage on October 14.
The drug’s generic name is oveporexton.
Takeda is expected to launch it in Japan by the end of the year.
The company forecasts peak sales of $2 billion to $3 billion.
- Who
- Takeda Pharmaceutical developed the drug.
- What
- Ozeifuru, an oral treatment for narcolepsy type 1, is scheduled for Japanese insurance coverage.
- When
- October 14, 2026.
- Where
- Japan.
- Why
- It is intended to treat narcolepsy type 1, a chronic sleep disorder that causes overwhelming sleepiness.
This story does not have two clearly opposing sides.
Ozeifuru had received approval in China and the United States.
The drug was scheduled to be listed for insurance coverage in Japan.
The drug was expected to launch in Japan.
- Drug
- Ozeifuru (oveporexton)
- Indication
- Narcolepsy type 1
- Japanese coverage date
- October 14, 2026
- Peak sales forecast
- $2 billion to $3 billion
- Other approvals
- China and the United States